Namely, JAK1/2 mutations were associated with decreased Interferon-γ (IFN-γ) sensitivity of melanoma cells (15), and mutations in the gene encoding beta-2-microglobulin (B2M) to loss of surface expression of MHC-I and decreased antigen presentation (16). The gene discussed is B2M; the disease is melanoma.